Immatics widens Q3 2026 net loss to €76.0M as R&D spend climbs
The T-cell receptor therapeutics company reports higher research costs and a warrant liability charge, while holding cash and other financial assets of roughly €472M at 30 September.
Immatics N.V. has filed unaudited interim financial statements for the three and nine months to 30 September 2026, showing a third-quarter net loss of €76.0M. That compares with a loss of €50.5M in the same quarter of 2025.
Research and development expense was the main driver, rising to €70.3M from €47.2M a year earlier. The company also booked a €3.3M charge related to a warrant liability.
On the balance sheet, cash and cash equivalents stood at €276.6M and other financial assets at €195.7M, together about €472M. Shareholders' equity was €438.5M.
Collaboration revenue for the first nine months of the year fell to €23.7M, from €28.5M in the corresponding period of 2025. The material available does not break down the revenue decline or the increase in R&D spending by programme.
Why it matters
- Partners and competitors can read the sharp rise in quarterly R&D expense as a sign of higher development activity, though the filing summary does not specify which programmes drove it.
- Lower collaboration revenue means the company's funding depends more on its existing cash and financial asset reserves of about €472M.
- Teams tracking cell therapy developers should check the full interim report for programme-level detail, as it is not covered in the information available.
Company's press release (SEC filing): Immatics N.V. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
